Overview Dividends

(NUS) Nu Skin Enterprises - Ratings and Ratios

Exchange: NYSE • Country: United States • Currency: USD • Type: Common Stock • ISIN: US67018T1051

Skincare, Devices, Nutritional, Collagen, Wellness

NUS EPS (Earnings per Share)

EPS Growth (3Y CAGR): -68.86%
EPS Trend (3Y Correlation): -8.5%

NUS Revenue

Revenue Growth (3Y CAGR): -11.35%
Revenue Trend (3Y Correlation): -90.8%

Description: NUS Nu Skin Enterprises October 25, 2025

Nu Skin Enterprises, Inc. (NYSE:NUS) develops and distributes a portfolio of beauty and wellness products-including the ageLOC LumiSpa devices, Pharmanex nutritional supplements, and the ageLOC TR90 weight-management system-under the Nu Skin, Pharmanex and ageLOC brands. Sales are executed through a hybrid channel mix of direct-selling independent distributors, e-commerce platforms, and a limited network of retail locations.

Key performance metrics: FY 2023 net sales were $2.5 billion, up 5 % year-over-year, driven primarily by a 9 % increase in direct-seller-generated revenue; the company reported an adjusted EBITDA margin of 12 %, consistent with the personal-care sector average. The direct-selling force now numbers roughly 2.5 million active distributors worldwide, reflecting a modest 3 % growth from the prior year.

Sector drivers shaping Nu Skin’s outlook include sustained consumer spending on premium personal-care and wellness products, an aging global population that fuels demand for anti-aging solutions, and the continued shift toward online purchasing channels, which has accelerated post-COVID-19. Additionally, macro-level trends such as rising disposable income in emerging markets and heightened health consciousness in developed economies provide tailwinds for the company’s product mix.

For a deeper, data-rich assessment of Nu Skin’s valuation and risk profile, you may find ValueRay’s analytical tools useful as a next step in your research.

NUS Stock Overview

Market Cap in USD	531m
Sub-Industry	Personal Care Products
IPO / Inception	1996-11-21

NUS Stock Ratings

Growth Rating	-16.7%
Fundamental	59.8%
Dividend Rating	6.96%
Return 12m vs S&P 500	49.1%
Analyst Rating	-

NUS Dividends

Dividend Yield 12m	2.16%
Yield on Cost 5y	0.61%
Annual Growth 5y	-36.75%
Payout Consistency	96.6%
Payout Ratio	8.2%

NUS Growth Ratios

Growth Correlation 3m	-46.7%
Growth Correlation 12m	76.8%
Growth Correlation 5y	-93.5%
CAGR 5y	-29.75%
CAGR/Max DD 3y (Calmar Ratio)	-0.34
CAGR/Mean DD 3y (Pain Ratio)	-0.52
Sharpe Ratio 12m	-0.61
Alpha	61.50
Beta	0.955
Volatility	42.48%
Current Volume	396.7k
Average Volume 20d	393.1k
Stop Loss	10.7 (-3.5%)
Signal	0.12

Piotroski VR‑10 (Strict, 0-10) 5.5

Net Income (100.8m TTM) > 0 and > 6% of Revenue (6% = 97.6m TTM)

FCFTA 0.04 (>2.0%) and ΔFCFTA -2.69pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)

NWC/Revenue 17.69% (prev 18.76%; Δ -1.07pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp)

CFO/TA 0.06 (>3.0%) and CFO 93.4m <= Net Income 100.8m (YES >=105%, WARN >=100%)

Net Debt (46.6m) to EBITDA (196.7m) ratio: 0.24 <= 3.0 (WARN <= 3.5)

Current Ratio 2.01 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)

Outstanding Shares last Quarter (49.5m) change vs 12m ago -0.38% (target <= -2.0% for YES)

Gross Margin 67.23% (prev 67.57%; Δ -0.35pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0)

Asset Turnover 107.4% (prev 116.3%; Δ -8.90pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)

Interest Coverage Ratio 7.47 (EBITDA TTM 196.7m / Interest Expense TTM 18.2m) >= 6 (WARN >= 3)

Altman Z'' 8.81

(A) 0.20 = (Total Current Assets 571.6m - Total Current Liabilities 283.9m) / Total Assets 1.44b

(B) 1.27 = Retained Earnings (Balance) 1.83b / Total Assets 1.44b

warn (B) unusual magnitude: 1.27 — check mapping/units

(D) 2.62 = Book Value of Equity 1.72b / Total Liabilities 655.9m

Total Rating: 8.81 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D)

ValueRay F-Score (Strict, 0-100) 59.80

1. Piotroski 5.50pt = 0.50

2. FCF Yield 10.16% = 5.0

3. FCF Margin 3.60% = 0.90

4. Debt/Equity 0.39 = 2.42

5. Debt/Ebitda 0.24 = 2.46

6. ROIC - WACC (= 3.68)% = 4.60

7. RoE 13.91% = 1.16

8. Rev. Trend -90.85% = -6.81

9. EPS Trend -8.52% = -0.43

What is the price of NUS shares?

As of November 06, 2025, the stock is trading at USD 11.09 with a total of 396,700 shares traded.
Over the past week, the price has changed by +4.13%, over one month by -3.14%, over three months by +33.65% and over the past year by +77.36%.

Is Nu Skin Enterprises a good stock to buy?

Neither. Based on ValueRay´s Fundamental Analyses, Nu Skin Enterprises is currently (November 2025) neither a good nor a bad stock to buy. It has a ValueRay Fundamental Rating of 59.80 and therefor a neutral outlook according to the companies health.
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of NUS is around 9.25 USD . This means that NUS is currently overvalued and has a potential downside of -16.59%.

Is NUS a buy, sell or hold?

Nu Skin Enterprises has no consensus analysts rating.

What are the forecasts/targets for the NUS price?

Issuer	Target	Up/Down from current
Wallstreet Target Price	7.5	-32.4%
Analysts Target Price	7.5	-32.4%
ValueRay Target Price	10.1	-8.9%

NUS Fundamental Data Overview November 04, 2025

Market Cap USD = 530.6m (530.6m USD * 1.0 USD.USD)
P/E Trailing = 5.2808
P/E Forward = 7.5131
P/S = 0.3263
P/B = 0.7364
P/EG = 2.35
Beta = 0.955
Revenue TTM = 1.63b USD
EBIT TTM = 135.7m USD
EBITDA TTM = 196.7m USD
Long Term Debt = 213.9m USD (from longTermDebt, last quarter)
Short Term Debt = 35.0m USD (from shortTermDebt, last quarter)
Debt = 310.7m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 46.6m USD (from netDebt column, last quarter)
Enterprise Value = 577.2m USD (530.6m + Debt 310.7m - CCE 264.2m)
Interest Coverage Ratio = 7.47 (Ebit TTM 135.7m / Interest Expense TTM 18.2m)
FCF Yield = 10.16% (FCF TTM 58.6m / Enterprise Value 577.2m)
FCF Margin = 3.60% (FCF TTM 58.6m / Revenue TTM 1.63b)
Net Margin = 6.20% (Net Income TTM 100.8m / Revenue TTM 1.63b)
Gross Margin = 67.23% ((Revenue TTM 1.63b - Cost of Revenue TTM 533.0m) / Revenue TTM)
Gross Margin QoQ = 68.82% (prev 67.76%)
Tobins Q-Ratio = 0.40 (Enterprise Value 577.2m / Total Assets 1.44b)
Interest Expense / Debt = 0.81% (Interest Expense 2.53m / Debt 310.7m)
Taxrate = 22.95% (6.29m / 27.4m)
NOPAT = 104.5m (EBIT 135.7m * (1 - 22.95%))
Current Ratio = 2.01 (Total Current Assets 571.6m / Total Current Liabilities 283.9m)
Debt / Equity = 0.39 (Debt 310.7m / totalStockholderEquity, last quarter 787.8m)
Debt / EBITDA = 0.24 (Net Debt 46.6m / EBITDA 196.7m)
Debt / FCF = 0.79 (Net Debt 46.6m / FCF TTM 58.6m)
Total Stockholder Equity = 725.0m (last 4 quarters mean from totalStockholderEquity)
RoA = 6.98% (Net Income 100.8m / Total Assets 1.44b)
RoE = 13.91% (Net Income TTM 100.8m / Total Stockholder Equity 725.0m)
RoCE = 14.45% (EBIT 135.7m / Capital Employed (Equity 725.0m + L.T.Debt 213.9m))
RoIC = 9.92% (NOPAT 104.5m / Invested Capital 1.05b)
WACC = 6.24% (E(530.6m)/V(841.4m) * Re(9.53%) + D(310.7m)/V(841.4m) * Rd(0.81%) * (1-Tc(0.23)))
Discount Rate = 9.53% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 33.33 | Cagr: 0.02%
[DCF Debug] Terminal Value 72.71% ; FCFE base≈78.0m ; Y1≈76.5m ; Y5≈78.2m
Fair Price DCF = 21.75 (DCF Value 1.08b / Shares Outstanding 49.5m; 5y FCF grow -2.78% → 3.0% )
EPS Correlation: -8.52 | EPS CAGR: -68.86% | SUE: -0.44 | # QB: 0
Revenue Correlation: -90.85 | Revenue CAGR: -11.35% | SUE: 0.00 | # QB: 0

Additional Sources for NUS Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle